Top Markets
Coin of the day
Ulisse Biomed S.p.A. Ulisse Biomed S.p.A.

Ulisse Biomed S.p.A.

UBM
Clasificación en acciones #29599
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in... Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Precio por acción
$0.93739396
Última sincronización: 2026-01-08
Capitalización bursátil
$20.44M
Cambio (1 día)
0.60%
Cambio (1 año)
-6.88%
País
IT
Comercio Ulisse Biomed S.p.A. (UBM)

Categoría

Ganancias de Ulisse Biomed S.p.A. (UBM)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Ulisse Biomed S.p.A., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Ulisse Biomed S.p.A. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
- -
KR